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Abstract: Alcohol affects the symptoms, compliance and comorbidities as well as the safety and
efficacy of treatments in psoriatic patients. In this review, we aim to summarize and link clinical
observations with a molecular background, such as signaling pathways at the cellular level and
genetic variations, and to provide an overview of how this knowledge could influence our treatment
selection and patient management.
Keywords: psoriasis; alcohol; addiction; compliance; genetic factors; keratinocytes; immune cells
1. Introduction
Psoriasis, with a prevalence of 1–4%, is one of the most common chronic inflammatory
skin diseases; however, it is not only the disorder of the skin but also a systemic one, asso-
ciated with significant comorbidities that influence disease pattern, prognosis, treatment
and management [1]. Importantly, the severity of psoriasis greatly affects the life quality of
patients as well, where impairment is most commonly measured by the Dermatological
Life Quality Index (DLQI) [2] and takes a prime position in patient management.
Regarding its clinical phenotypes, chronic plaque-type, guttate, erythrodermic and
pustular psoriasis can be distinguished, while based on the localization, other variants
such as inverse or flexural psoriasis, palmoplantar psoriasis, sebopsoriasis and nail psori-
asis can be described as well [3]. According to the age of onset, psoriasis can be further
subclassified into early-onset (40 years) and late-onset (>40 years) groups, underpinned
by findings that a more pronounced genetic background is found in the early-onset one [4].
The severity of psoriasis may range from a few lesions to the involvement of the whole
body and can be specified by several parameters, including the size of the affected area
and inflammation of the lesions, which are all reflected in the Psoriasis Area Severity
Index (PASI) score. Such scoring is the basis for distinguishing mild, moderate and severe
psoriasis and has been widely used (in combination with the DLQI) for treatment selection
and monitoring treatment response [5]. Therapeutic choices include topical therapies with
classical alternatives such as keratolytics and local corticosteroids possibly in combination
with vitamin D3 analogs [6] and calcineurin inhibitors. Further options cover photother-
apy, oral systemic agents (methotrexate, acitretin, cyclosporine and small molecules, e.g.,
fumaric acid ester) and biological agents [7]. However, the International Psoriasis Council
published a simplified statement in 2020, which instead of the mild, moderate and severe
classification defines patients suitable for systemic therapy based on meeting at least one
of three criteria: more than 10% of body surface area is affected, psoriasis at special sites
(scalp, face, palms and soles or genitalia) and non-response to topical therapy [8].
Int. J. Mol. Sci. 2021, 22, 4987. https://doi.org/10.3390/ijms22094987 https://www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2021, 22, 4987 2 of 14
In the development of psoriasis, an interplay between multiple genetic and envi-
ronmental factors (e.g., stress, nutritional status and mechanical trauma) are involved,
of which—despite an increasing knowledge—many are yet to be characterized in more
details. The relationship between alcohol use and psoriasis is one of the prime examples for
this, raising provoking questions such as, “Does psoriasis drive people into uncontrolled
alcohol consumption?” or vice versa, “Does the presence of alcohol and alcohol-induced
organ changes drive the development of psoriasis?”. Therefore, in this review, we aim to
reveal the many situations in which alcohol consumption has to be taken into consideration
for the successful management of chronic plaque-type psoriasis (later referred simply as
psoriasis) patients. Moreover, we deliver a comprehensive overview of how the interaction
of alcohol with symptom severity and medication efficacy may be determined at the level
of molecular mechanisms and genetic background.
Using PubMed and Google Scholar with the term “psoriasis”—in combination with
“alcohol”, “genetics”, “comorbidities”, “mental disorder”, “stress”, “adherence”, “com-
pliance”, “keratinocyte”, “immune cell”, “management” and “therapy”—we focused on
all relevant publications in English from the past 10 years (March 2011 to March 2021),
included highly-cited older publications as well as additional reports from the references
in systematic reviews.
2. Role of Alcohol in Psoriasis
It has been reviewed and reported in many studies that significant alcohol intake is
an independent risk factor in the onset of psoriasis [9], presuming and partly revealing
numerous mechanisms in the background of the disease. Alcohol use is also able to worsen
the already-existing disease via increased tumor necrosis factor-↵ (TNF↵) production and
triggers alcohol-related disorders (e.g., alcoholic liver disease); furthermore, the treatment
response in psoriasis is less favorable in cases of considerable alcohol consumption as
these data have also been explored in a meta-analysis [10]. In alcoholics, the activity
of pro-inflammatory cytokines was found to be elevated, which might contribute to the
inflammatory process in psoriatic patients [11].
2.1. Alcohol and Its Relation to Psoriasis Symptoms at the Cellular Level
Ingested alcohol (i.e., ethanol) can be metabolized primarily to acetaldehyde by the
alcohol dehydrogenase (ADH) enzyme family, catalase and cytochrome P450 isoform
2E1 (CYP2E1) and further oxidized into acetate and acetyl coenzyme A (acetyl-CoA) by
the enzyme aldehyde dehydrogenase (ALDH) [12]. Acetyl-CoA serves as a precursor
for the generation of acetone, which is formed by the decarboxylation of acetoacetic
acid [13]. During ethanol metabolism, the formation of reduced nicotinamide adenine
dinucleotide (NADH) is increased which delays the degradation of acetyl-CoA and thus
elevates acetone blood levels [13]. Ethanol and its metabolites (acetaldehyde and acetone)
can be both initiating and exacerbating factors at the cellular level in the inflammatory
processes of psoriasis.
2.1.1. Alcohol and Keratinocytes
It is known that from consumed and digested ethanol a measurable amount finds its
way to and within the human skin, being secreted by the eccrine glands (primarily sweat
glands) or during passive diffusion [14–16]. The potential effects of transdermal alcohol
have been investigated in vitro and found that ethanol and its metabolite acetone increase
the proliferation and mRNA expression of proliferation-associated genes (↵5 integrin,
cyclin D1 and keratinocyte growth factor receptor [KGFR]) in HaCaT keratinocytes and
may thus increase the permeability of the skin, disrupting its barrier function [17]. In
addition, alcohol also has an effect on lipid metabolism: the risk of high triglycerides
is increased with increasing alcohol consumption, and thus it may also affect the lipid
composition of the skin barrier [18].
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Reactive oxygen species (ROS) generated in the skin of alcohol consumers during
ethanol metabolism and acetaldehyde formation are able to regulate the mitogen-activated
protein kinase/activator protein 1 (MAPK/AP1), the nuclear factor kappa-B (NF-B) and
the Janus kinase/signal transducers and activators of transcription (JAK/STAT) signal
transduction cascades [19]. This oxidative stress, together with TNF↵, one of the major
cytokines in psoriasis, results in a positive feedback loop, leading to additional ROS for-
mation and interleukin (IL)-1, IL-6 and IL-8 inflammatory cytokine production in primary
human keratinocytes, thus contributing to the pathogenesis of psoriasis [20].
AP1 proteins are expressed in a differentiation-stage-dependent manner in keratinocytes.
Acetaldehyde activates c-Jun mRNA and protein levels and induces Jun/AP1 DNA binding
activity in oral keratinocytes, therefore, it is reasonable to suppose that ethanol may disturb
keratinocyte proliferation and is involved in the aggravation of psoriasis [21,22].
The family of protein kinase C (PKC) isoenzymes regulates important cellular func-
tions including cell growth, differentiation and cytokine production [23]. Characteristic
PKC isoenzyme patterns were described in HaCaT cells during cell proliferation and
differentiation [24] and it is generally accepted that the down-regulated PKC subspecies
in psoriasis may be involved in aberrant cell growth and differentiation [25–27]. The
interaction of ethanol with PKC is complex and the results are generally contradictory
due to the various species/tissues and different alcohol exposures that were used in the
experiments [28–33]; however, it is worth noting that through the regulation of PKCs,
ethanol might negatively affect the cell cycle and tissue growth in psoriasis.
2.1.2. Alcohol and the Immune System
Ethanol and its previously listed metabolites also affect both innate and adaptive
immunity and may have a direct or indirect impact on immune cells.
Ethanol was found to augment the uric acid-induced NLR family pyrin domain-
containing 3 (NLRP3) inflammasome activation and IL-1  production through the repres-
sion of the aryl hydrocarbon receptor (AhR) in macrophages [34], increase the proliferation
and induce the release of interferon-  (IFN ) in lymphocytes and elevate the production
of TNF↵ from peripheral blood monocytes and macrophages [15,19]. The soluble form of
TNF↵ is released by the TNF↵-converting enzyme (TACE), the overexpression of which
was described in psoriatic lesions [35]. Furthermore, excessive alcohol consumption may
contribute to its increased expression in peripheral blood mononuclear cells (PBMCs) and,
in consequence, to elevated plasma soluble TNF- receptor 1 (sTNF-R1) concentrations in
patients with psoriasis [36].
The relationship between keratinocytes and immune cells is well known in the path-
omechanism of psoriasis. When supernatants of keratinocytes isolated from the skin
of psoriatic patients were co-cultured with HUT 78 lymphocytes, findings showed in-
creased protein levels of IFN , transformed growth factor-↵ (TGF↵) and IL-6 after ethanol
treatment, and suggested that ethanol also affects the epidermal and immune cell commu-
nication by triggering the T-helper (Th) 1 response [37].
Murine models also support a role for ethanol in skin inflammation. In vitro stud-
ies showed that the expression of C-C motif chemokine ligand 20 (CCL20) (an essential
chemoattractant molecule in psoriasis) was induced in normal murine epidermal ker-
atinocytes when the medium was supplemented with ethanol [38]. Moreover, the skin of
ethanol-administrated hairless mice is characterized by attenuated skin hydration with
significantly increased transepidermal water loss, up-regulated expression of TNF receptor
2 (TNFR2), decreased production of ceramide and type I collagen and increased plasma
TNF↵ concentrations. In addition, anti-TNF↵ antibody treatment ameliorated the impaired
skin barrier function in these mice [39]. Chronic ethanol feeding negatively affects both
the number and the function of murine epidermal and dermal T cell subsets [40]. Im-
munostaining analysis revealed that in the skin of C57BL/6 mice receiving 5% ethanol in
their drinking water, epidermal T-lymphocyte infiltration and IL-17A, TNF↵ and CCL20
mRNA expressions were increased. Moreover, when these mice received both ethanol and
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topical imiquimod (imiquimod-induced skin inflammation is currently the most widely
accepted psoriasis animal model) [41], prominent epidermal thickening and more severe
skin inflammation were observed with elevated expression of IL-17A, IL-22, IL-23 and
S100A9 [38].
Altogether, these data suggest that alcohol consumption can adversely affect psori-
asis symptoms at the cellular level by influencing the proliferation, differentiation and
skin barrier function of keratinocytes and inducing immune dysfunction via altering the
production of inflammatory cytokines by immune cells. The potential role of ethanol
and its metabolites in the pathomechanism of psoriasis at the cellular level is overviewed
in Figure 1.
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patients with psoriasis.
2.2. Alcohol and Patient Compliance
Patient compliance and therapeutic adherence are key factors in the comprehensive
management of psoriasis and the definition of treatment success and disease prognosis.
Patient adherence is defined as the consistent behavior of an individual that matches the
recommendations agreed upon with the treating physician. Factors influencing treatment
adherence can be patient-related, physician-related or external ones [42]. Many external fac-
tors may interfere with patient compliance, such as information provided to an individual
on the disease, environmental influence or limitation caused by repetitive alcohol consump-
tion (abuse), etc.; however, practical reviews examining psoriatic treatment adherence with
an established scientific approach are limited.
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In their open prospective study, Zaghloul and Goodfield assessed treatment compli-
ance in psoriatic patients by direct questioning. They reported mean medication adherence
to be around 60% and identified moderate alcohol intake (besides other factors such as
being fed-up or forgetful, having facial symptoms and more extended disease form) as the
main reason for non-adherence [43].
Carrol et al. suggested that in psoriasis the more an individual adheres to treat-
ment, the better the reduction in disease severity [44]. While they examined the effect
of therapeutic adherence to changes in psoriasis severity, they learned and concluded
that non-adherence altered clinical trial data toward ineffectiveness, which might have
been improved by special interventions such as motivations for self-reports or electronic
monitoring [44].
In their critical review, Thorneloe et al. searched for the factors associated with and the
extent of non-adherence in psoriasis. Keeping in mind the methodological limitations aris-
ing from the included studies, they drew a tentative conclusion that suboptimal treatment
adherence was determined by psychological factors (e.g., psychological distress) rather
than by quality of life alterations [45].
3. Role of Psoriasis in Alcohol Consumption
Evidence also exists that severe forms of psoriasis may lead to increased alcohol
use [46]. In a robust search covering almost 40 years of reports, alcohol, along with other
behavioral factors, was found to have an independent association with psoriasis that may
influence several comorbidities of the disease as well [47].
3.1. Stress and Mental Disorders in Psoriatic Patients
Psychosocial stress, as one of the most important extrinsic factors that affect psoriasis,
can prolong or even trigger psoriasis in susceptible individuals [3]. The etiopathogenesis
of the psoriasis–psychological stress interaction includes the central and the peripheral
hypothalamic–pituitary–adrenal (HPA) axis escalating inflammatory cytokines; activation
of the sympathetic nervous system resulting in a defective adrenergic response and re-
distribution of leucocytes, moreover the stimulation of neuronal growth and alteration in
neuropeptide and neurotrophin expression [48].
Chronic stress, however, exacerbates not just psoriasis itself, but also many mental
disorders. The prevalence of psychiatric conditions in psoriasis may range from 24% to
90% [49]. A population-based cohort study in the UK found that patients with psoriasis
have an increased risk of depression, anxiety and suicidality compared to the general
population [50]. Out of these risks, the presence of depression escalates when pruritus
is present [51], but in overviewing the relevant literature, data also show that more than
50% of the psoriatic population have sleep disorders [52] and up to 71.3% face sexual
dysfunction [53]. Moreover, somatoform disorders, schizophrenia/other psychoses and
bipolar disorder are also on the list of mental disorders linked to psoriasis [54]. It is needless
to say that as a result of stress, quality of life diminishes and the psychosocial comorbidities
promote more stress, a vicious circle that often precipitates substance dependence or abuse.
However, despite the strong connection between alcohol consumption and psychological
distress (associated with worry), only a small proportion of patients seek help or attend
appointments for these matters [55].
3.2. Alcohol Consumption and Addiction in Psoriatic Patients
Susceptibility to different addictions seems to be increased in the psoriatic population.
Conducting a study based on a self-reported screening test by a validated questionnaire
of the six most common addictions in Germany with 102 psoriatic patients, Eyerich et al.
found that the risk of alcohol abuse, nicotine abuse and gambling were significantly
higher in the study group compared to the general population [56], defining the need
for public health strategies and interdisciplinary approaches to tackle the vulnerability of
psoriasis patients.
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McAleer et al. investigated the association between alcohol intake and disease severity
by applying validated questionnaires (Michigan Alcohol Screening Test, Alcohol Use Dis-
orders Identification Test—AUDIT, CAGE) and biomarkers, such as  glutamyl-transferase
( GT) and carbohydrate-deficient transferrin (CDT), on a study cohort of 135 patients with
moderate to severe chronic plaque psoriasis [57]. However, they did not find a significant
correlation between excessive alcohol consumption and disease severity—in contrast to
a study by Kirby et al. [58]—and revealed a nearly identical range (22–32%) of alcohol
misuse among psoriatic patients [57]. Meanwhile, in another small study population us-
ing whole-blood phosphatidylethanol (PEth) to verify alcohol intake, the level of alcohol
consumption correlated with the extent of psoriasis [59].
Applying the AUDIT and CAGE questionnaires [60] to facilitate the recognition of
potential alcohol problems, we involved 214 psoriasis patients in our study to assess alcohol
use in our psoriasis population; however, only 27 confirmed regular alcohol use, while
34 denied drinking alcohol at any time. As the prevalence of alcohol consumption was
found to be over 40% in the Hungarian population [61], it is very unlikely that the results
from our psoriasis population were indeed valid, further suggesting that integrating and
dealing with the drinking habits of psoriasis patients faces great limitations.
4. Genetic Factors behind Alcohol Consumption in Psoriatic Patients
Explicit genetic background is an integral part of the etiology of alcoholism. The
genetic determination based on twin studies is about 45–60% [62], and further data from
adoption and animal studies also supports its importance [63–65].
In the pre-GWAS era, gene identification efforts faced substantial difficulties due
to relatively small sample sizes and the low hit rate of the assumed candidate genes in
association with alcohol use disorder (AUD) [66]; however, the introduction of GWAS
arm-in-arm with the establishment of large biobanks and international collaborations
brought a breakthrough in this field of research. According to the literature, there are
two main categories of candidate genes selected for genetic association studies related to
AUD: genes involved in the first category play a functional role in the central nervous
system’s (CNS) response to alcohol or other addictive substances (gamma-aminobutyric
acid type A receptor subunit gamma1 [GABRG1] and GABR subunit alpha2 [GABRA2],
µ-opioid receptor 1 [OPRM1], etc.) [67–69]; while genes belonging to the second category
are essential in alcohol metabolism (ADH4, ADH1B, ALDH2) [70–73].
While the genetic aspect is pivotal in the etiology of psoriasis, the question of whether
the association between psoriasis and increased alcohol consumption may be driven by
genetic factors has not yet been answered. Therefore, we conducted a population-based
case-control study including 3743 (776 psoriasis and 2967control) subjects and evaluated the
relationship between 23 increased alcohol intake and dependence-related single nucleotide
polymorphism (SNP) in a Hungarian psoriasis group. Our results suggested that genetically
defined high-risk individuals for alcohol consumption are more common in the psoriasis
population [74]. We found that the frequency of C allele of the genetic variant rs1229984 in
the gene coding ADH1B had a significantly higher prevalence compared to the Hungarian
general population. This coding variant in ADH1B (Arg48His) results in a higher catalytic
activity of the enzyme that may also lead to changes in the levels of harmful acetaldehyde
following alcohol ingestion (Figure 2A). As supported by an Australian study involving
4597 twins, such carriers reported a lower prevalence of flushing after alcohol, consumed
alcohol on more occasions, had a higher maximum number of alcoholic drinks in a single
day and higher overall alcohol consumption than those with the less common A-allele
(48His) [75].
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Figure 2. (A) Genetic variant rs1229984 (ADH1B gene), showing a significantly higher prevalence in
our Hungarian psoriasis group (n = 776) compared to the Hungarian general population (n = 2967,
leads to increased catalytic activity of the ADH enzyme that ay alter the levels of ethanol and
acetaldehyde. (B) Possible involvement of genetic variant rs1799971 (OPRM1 gene), found to increase
the risk of familial psoriasis by twofold compared to sporadic cases in our Hungarian psoriasis group,
in the psoriasis–itch–stress–alcohol consumption cycle.
By stratifying the psoriasis group, significant results were also found in the case of
rs1799971 (OPRM1) when familial cases were compared to sporadic cases. Allele 118G
increased the risk of familial psoriasis by twofold compared to sporadic cases. OPRM1
encodes the µ-opioid receptor, which upon activation by its ligands—such as opioids
—modulates the dopamine system [76]. It is implicated in complex behavior patterns such
as alcohol dependence [77,78] and alcohol dependence associated impulsivity [68]. In
individuals carrying 118G, stimulation, sedation and positive mood levels after alcohol
intake were significantly higher than in controls [79]. Importantly, OPRM1 is also involved
in itch [80], a sensation reported by 70–90% of patients with psoriasis [81], calling for
further studies to assess the psoriasis–itch–disease associated stress–alcohol consumption
circle both at the level of clinical as well as of genetic studies [82] (Figure 2B).
5. Alcohol Affecting Psoriasis Therapies
While cyclosporine has no known interaction with alcohol and targeted therapies are
a safe choice not only to achieve a specific and preferred therapeutic response but also
in patients with impaired liver functions—the very rare cases of autoimmune hepatitis
observed in patients receiving TNF↵ inhibitor treatments is not related to alcohol con-
sumption [83]—prescribing acitretin and methotrexate needs special attention in psoriasis
patients with alcohol problems.
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5.1. Acitretin
Regarding acitretin, there is an enzymatic overlap between ethanol detoxification
and retinoic acid biosynthesis. Although ADHs and ALDHs have different substrate
preferences, the competition of ethanol, acetaldehyde and retinoids for the same metabolic
enzymes potentially may result in teratogenicity and altered therapeutic response in
psoriatic patients [84–86]. The formation of retinaldehyde from retinol also requires ADHs
and retinol dehydrogenases (RDHs) and the oxidation of retinaldehyde to retinoic acid
is catalyzed by retinaldehyde dehydrogenases (RALDHs or ALDHs) [87]. In therapy,
acitretin has replaced its ethyl ester, etretinate, in the treatment of various keratinoid
disorders such as psoriasis, as it is not stored in the adipose tissue, has a shorter half-life
and is consequently eliminated more rapidly from the human body [88–90]. Interestingly,
although etretinate is a prodrug of acitretin, Chou et al. showed that the conversion
of etretinate to acitretin is not an irreversible process [91]. Moreover, in rats, etretinate
formation from acitretin was significantly enhanced by simultaneous administration of
varying amounts of ethanol, and plasma etretinate concentrations were correlated with
ethanol doses but not with plasma acitretin levels [91]. Similar results were observed in
in-vitro experiments on human liver cells [91] and in psoriatic patients receiving acitretin
therapy, leading to the conclusion that alcohol consumption may enhance the etretinate
formation from acitretin, in which ethanol could be an important contributing factor [92,93].
A possible underlying mechanism is that acetyl-CoA formed during ethanol metabolism
enhances the conversion of acitretin to etretinate; thus, ethanol seems to act as an acetyl
donor rather than an enzyme inducer during the ethyl esterification of acitretin [92,94].
5.2. Methotrexate
Methotrexate is known for causing non-alcoholic fatty liver disease (NAFLD); more-
over, obesity (another risk factor for NAFLD) is also more prevalent among psoriasis
patients [95,96], suggesting that indeed there may be a subgroup of patients predisposed to
developing hepatotoxicity as a systemic manifestation of psoriasis itself and to methotrex-
ate therapy. Although the regular follow-up of patients by measuring the levels of serum
aminotransferases and performing regular FibroScan examinations makes methotrexate
safe [97], elevated liver enzymes due to obesity and/or (possibly unreported) alcohol use
may initiate the doctor to terminate the otherwise effective methotrexate treatment, even
though studies suggest that moderate drinkers are not at risk when taking methotrexate.
Among numerous studies with a relatively low number of patients often delivering con-
flicting results, a study of 11839 patients revealed that in patients taking methotrexate in
a maximum dose of 25mg/week, consuming less than 14 units of alcohol did not appear
to be associated with an increased risk, between 15 and 21 units was associated with a
possibility of increased risk and drinking >21 units per week led to significantly increased
rates of hepatotoxicity (adjusted HR [95% CI] 1.85 [1.17–2.93]) marked by elevated serum
aminotransferases. For reference, a small glass of wine contains about 1.5 units, whereas a
can of beer or cider is 2 units [98]. However, just as patients and their comorbidities differ,
national and international guidelines also lack uniformity in advice on alcohol use with
methotrexate [99,100].
6. Patient Management
Although DLQI covers the most important aspects of a patient’s life, questions that
would reveal one’s relation to the use of obsessive agents and behaviors (such as “Do you
feel stress, and if so, how do you find relief from it?”) are not included in it. Given that
patients often feel themself humiliated when confessing about their alcohol-consuming
habits, both physicians and researchers face great challenges when investigating this
intimate topic; therefore, the general attitude that not speaking about it means it is not
existing has to be changed. Indeed, although moderate alcohol consumption is a globally
accepted social habit—except for in certain religious communities—the fact that alcohol
itself is a toxic and psychoactive substance should also not be ignored.
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While, except for methotrexate, regular alcohol use is not affecting the decision when
selecting therapy for our psoriasis patients, increasing data confirms its possible impact on
psoriasis symptoms, patient compliance and treatment effectiveness, for which we must
address all potentially relevant barriers and provide thorough and supportive education
for them. In their comprehensive guideline, Elmets et al. suggested that psoriatic patients
should be counseled about the limitation of alcohol use that bears the risk for more severe
disease and associated comorbidities (the strength of the recommendation was B and
the level of evidence was II–III). Furthermore, they concluded that since the amount of
alcohol also has an impact on concomitant pharmaceutical medications, it should therefore
also be considered (the strength of the recommendation was B and the level of evidence
was II–III). They further recommended that those with alcohol and concomitant nicotine
dependency should be referred to healthcare specialists for further support (the strength
of the recommendation was A). Additionally, they described that since the avoidance of
alcohol consumption can lead to the improvement of psoriasis, the dermatologist should
possibly play a supportive/helping role in informing the patients of that matter [47].
The need to offer help for psoriatic patients is further emphasized by Svantröm et al.,
who by introducing a neuro-endocrine approach in the alcohol dependence of psoriatic
patients, pointed out that several therapeutic modulators (e.g., dopamine [DA] 2 receptor
[R] and serotonin 5-hydroxytryptamine 2R [5-HT2R] antagonists and selective serotonin
reuptake inhibitors [SSRIs]) used in the treatment of alcoholism may affect the neuronal
transmission networks and biochemical pathways of alcohol metabolism and modulate
the number of biogenic amine receptors and circulating pro-inflammatory cytokines, with
a possible effect also on the inflammatory process in psoriasis. As so, they proposed the
idea that targeting neurotransmitter networks involved in both alcohol intake and the
inflammatory process could not only treat addiction but serve as a potential (adjuvant)
psoriasis therapy as well [101].
7. Conclusions
In summary, the contribution of alcohol to the development of psoriasis is unques-
tionable on every level (genetic and cellular level, disease onset and severity, treatment
options and adherence, prognosis, etc.). While the very limited “benchside” data suggests
further potential in addressing mechanisms with both patho(physiological) and therapeutic
relevance, from the clinician’s point of view, multidisciplinary strategies are needed to
identify and manage the affected population all the way from the “barside” to the “bedside”
and beyond. We strongly believe that supporting patients to make lifestyle changes may
lead to rewarding therapeutic accomplishments.
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